Navigation Links
Reportlinker Adds Amphotericin B - Comprehensive patent search
Date:2/1/2011

NEW YORK, Feb. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Amphotericin B - Comprehensive patent search

http://www.reportlinker.com/p0366172/Amphotericin-B---Comprehensive-patent-search.html

Eliminate unnecessary risk with the industry benchmark in comprehensive patent information.

Pipeline Developer is a regularly updated, professional patent search performed by our expert team, which not only identifies relevant patents, but delivers categorisation and interpretation, all delivered by a convenient online interface.

This Pipeline Developer report covers Amphotericin B

Amphotericin B indications: Potentially life-threatening fungal infections

Amphotericin B innovator: Apothecon (Fungizone); Astellas (Ambizone); Bristol Myers Squibb (Fungizone, Fungilin, Ampho-Moronal); Enzon (Abelcet); Zeneus (Abelcet); Gilead (AmBisome); Beacon (Amphocil); Orphan (Abelcet)

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.

Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information.

Pipeline Developer features: # Comprehensive pate
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reportlinker Adds Therapeutic Proteins to 2014
2. Reportlinker Adds Biochips - Products, Applications, Technologies and End-Use Markets Growth Analysis, 2009-2015
3. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
4. Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
5. Reportlinker Adds The 2011 Immunoprotein Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment
6. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers
7. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
8. Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration
9. Reportlinker Adds Vaccine Technologies and Global Markets
10. Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018
11. Reportlinker Adds Hospital General Radiology Census
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Ky. (PRWEB) March 03, 2015 Experts ... their schedules for one event: the Alltech REBELation exploring ... from May 17-20. Now in its 31st year, Alltech’s ... from 70 countries, and the opportunity to join the ... March 7 at 11:59 p.m. EST, at which point ...
(Date:3/3/2015)... March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), ... technologies and products for advanced microarray diagnostics, today ... CFE  to its Management team. In his capacity ... its transition from a development stage to a ... advance the Company,s capital market strategy and to ...
(Date:3/3/2015)... March 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... the development of and commercialization of regenerative cell therapies ... announced today that it has received the final payment ... Holdings, Inc. (OTC Bulletin Board: AMBS ). ... made the final payments due to Regenicin in the ...
(Date:3/3/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") ... Opinion on Biological Therapy , Dr. Michael Chopp ... at the Henry Ford Hospital in Detroit, ... has the capacity to promote CNS and peripheral nervous ... to neurological recovery in each case.  They pointed out ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Sept. 8 Don Margolis, Chairman of,The Repair ... based in,Bangkok, Thailand told The Wall Street Transcript ... future profits inside the stem cell,research sector will ... five years, even for,companies specializing in Repair Stem ...
... 7th International ... Symposium on Uveitis in Germany, ZURICH, Switzerland, Sept. ... today announced that the,company has successfully completed its Phase I ... indications. In,April 2008, ESBATech initiated the Phase I study designed ...
... RNA levels, following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus ... Copegus(R) -, ... ... 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces the preliminary results of the fourth cohort ...
Cached Biology Technology:Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... 2013 Disulfiram was the first medication approved for ... works, at least in part, by preventing the metabolism ... in the body quickly cause unpleasant symptoms, including nausea, ... a very strong incentive to avoid drinking. ...
... the fate of the original Otom inhabitants of Xaltocan, ... unknown. Researchers have long wondered whether they assimilated with ... to new anthropological research from The University of Texas ... the answers may lie in DNA. Following this line ...
... Thailand and Morocco have found that DHEA-S may prevent ... patients. In a report appearing in the February 2013 ... they describe how a network of steroid molecules found ... infection leading to brain damage. This suggests that treatment ...
Cached Biology News:Disulfiram: New support for an old addiction drug 2Aztec conquest altered genetics among early Mexico inhabitants, new DNA study shows 2A 'neurosteroid' found to prevent brain injury caused by HIV/AIDS 2
...
...
Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: